GM-3009

GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders.^[1][3][2] Its route of administration is unspecified.^[1] The drug is a highly potent agonist of the human KOR, with an affinity (K_i) of 0.9 nM or 87.3 nM depending on the radioligand and an EC₅₀Tooltip half-maximal effective concentration of 0.8 nM.^[2] In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo.^[2] GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents.^[2] It is being developed by Gilgamesh Pharmaceuticals.^[1][3] As of June 2024, it is in the preclinical research stage of development.^[1][3] The exact chemical structure of GM-3009 does not yet appear to have been disclosed.^[1]

GM-3009

Clinical data
Other names	GM3009
Routes of administration	Unspecified[1]
Drug class	κ-Opioid receptor agonist[2]

See also

• List of investigational hallucinogens and entactogens